Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
IFM 2018-01 trial: what clinicians have said so far
Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple Myeloma
- NCT03669445 ↗
- Unknown
- University Hospital, Toulouse
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on IFM 2018-01 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on IFM 2018-01 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- Toward a Risk-adapted Strategy to Cure Myeloma : An Intensive Program With Lenalidomide, Ixazomib, and Dexamethasone Plus Daratumumab as Extended Induction and Consolidation Followed by Lenalidomide Maintenance in Newly Diagnosed Standard Risk Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplant : a Phase II Study of the Intergroupe Francophone du Myélome (IFM)
- Phase
- Phase 2
- Status
- Unknown
- Conditions
- Multiple Myeloma
- Interventions
- Ixazomib; Lenalidomide; Dexamethasone; Daratumumab
- Arms
- four drugs combination · Experimental
- Enrollment
- 45 (estimated)
- Primary outcomes
- minimal residual disease-negativity rate
- Sponsor
- University Hospital, Toulouse
- Start
- Dec 31, 2018
- Primary completion
- Mar 2024 (estimated)
- Results posted
- No
- Registry record
- NCT03669445 · updated Jul 30, 2020